| Kirsten Garner, CNM, ARNP | |
|
4033 Talbot Rd S, Ste 430, Renton, WA 98055-5772 | |
| (425) 656-5321 | |
| (425) 656-5319 |
| Full Name | Kirsten Garner |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | 4033 Talbot Rd S, Renton, Washington |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295778132 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | AP30007076 (Washington) | Primary |
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831139724 PECOS PAC ID: 9537072814 Enrollment ID: O20031112000189 |
News Archive
Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.
A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.
Magnetic Resonance Imaging methods have been used widely in past decades as a safe, non-invasive and non-radioactive method of diagnosing CVDs.
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor mutations associated with lung cancer.
› Verified 3 days ago
| Entity Name | Swedish Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689612954 PECOS PAC ID: 0244138196 Enrollment ID: O20031230000187 |
News Archive
Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.
A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.
Magnetic Resonance Imaging methods have been used widely in past decades as a safe, non-invasive and non-radioactive method of diagnosing CVDs.
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor mutations associated with lung cancer.
› Verified 3 days ago
| Entity Name | Obstetrix Medical Group Of Washington Inc Ps |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861599573 PECOS PAC ID: 3577451947 Enrollment ID: O20040308000679 |
News Archive
Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.
A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.
Magnetic Resonance Imaging methods have been used widely in past decades as a safe, non-invasive and non-radioactive method of diagnosing CVDs.
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor mutations associated with lung cancer.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kirsten Garner, CNM, ARNP Po Box 34876, Seattle, WA 98124-1876 Ph: (425) 656-5321 | Kirsten Garner, CNM, ARNP 4033 Talbot Rd S, Ste 430, Renton, WA 98055-5772 Ph: (425) 656-5321 |
News Archive
Despite significant investment in research and development by pharmaceutical companies, the last decade has seen a marked decline in the number of drugs developed and approved for schizophrenia. A multi-day symposium at the New York Academy of Sciences on Wednesday, March 9 - Friday, March 11 will convene world-leading experts in clinical, translational, and basic neuroscience to address this problem by examining novel, state-of-the-art approaches to schizophrenia drug development.
A new study describes the identification of new compounds from a library, with inhibitory activity against several coronaviruses. This study shows the utility of this method, besides identifying compounds that not only inhibit viral shedding in SARS-CoV-2 cultures, but have an immunomodulatory effect that may be useful in mitigating the damaging cytokine storm typical of severe or critical COVID-19.
Magnetic Resonance Imaging methods have been used widely in past decades as a safe, non-invasive and non-radioactive method of diagnosing CVDs.
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced that it will collaborate with a pharmaceutical company to evaluate Trovagene's proprietary, urine-based, cell-free DNA technology for the detection of certain epidermal growth factor receptor mutations associated with lung cancer.
› Verified 3 days ago
Amy B Steers, CNM Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 660 Sw 39th St Ste 150, Renton, WA 98057 Phone: 425-690-3481 Fax: 425-690-9081 | |
Ann K Mcfarlane, CNM, MSN Advanced Practice Midwife Medicare: Medicare Enrolled Practice Location: 17722 Talbot Rd S, Renton, WA 98055 Phone: 425-690-3479 Fax: 425-690-9479 | |
Laurie Anne Rodenberg, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 17722 Talbot Rd S, Renton, WA 98055 Phone: 425-690-3479 Fax: 425-690-9479 | |
Carol Sherman Olivier, CNM, ARNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 4033 Talbot Rd S, Ste 430, Renton, WA 98055 Phone: 425-656-5321 Fax: 425-656-5319 | |
Farah Ka'healani Rivera, LM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 4300 Talbot Rd S, Renton, WA 98055 Phone: 206-222-0656 | |
Katherine A Carr, CNM, ARNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 4033 Talbot Rd S, Ste 440, Renton, WA 98055 Phone: 425-656-5321 Fax: 425-656-5319 |